In support of this notion, oncogenic KRAS can modulate ADAM17‐induced shedding of EGFR family ligands during colorectal and pancreatic cancers, and genetic targeting of ADAM17 in mouse models for these cancers suppresses tumorigenesis by abrogating EGFR family ligand production (Van Schaeybroeck et al, 2011; Ardito et al, 2012; Schmidt et al, 2018). Here, KRAS is linked to pancreatic neoplasm.